Eli Lilly and Company - LLY Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $559.08
  • Forecasted Upside: -5.41%
  • Number of Analysts: 21
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 18 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.82 (-0.14%)

This chart shows the closing price for LLY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Eli Lilly and Company Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LLY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LLY

Analyst Price Target is $559.08
▼ -5.41% Downside Potential
This price target is based on 21 analysts offering 12 month price targets for Eli Lilly and Company in the last 3 months. The average price target is $559.08, with a high forecast of $722.00 and a low forecast of $278.00. The average price target represents a -5.41% upside from the last price of $591.04.

This chart shows the closing price for LLY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 21 polled investment analysts is to moderate buy stock in Eli Lilly and Company. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 18 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 18 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 18 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 18 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 18 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 18 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 18 buy ratings
  • 2 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 18 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 18 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/29/2023Truist FinancialReiterated RatingBuy ➝ Buy$650.00Low
11/15/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$630.00Low
11/9/2023Deutsche Bank AktiengesellschaftInitiated CoverageHold$535.00Low
11/8/2023JPMorgan Chase & Co.Reiterated RatingOverweightLow
11/3/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$673.00 ➝ $722.00Low
10/23/2023CitigroupBoost TargetBuy ➝ Buy$525.00 ➝ $675.00Low
10/23/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$630.00Low
10/20/2023UBS GroupReiterated RatingBuy ➝ Buy$612.00 ➝ $710.00Low
10/11/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$640.00 ➝ $673.00Low
10/9/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$630.00Low
10/9/2023Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$615.00 ➝ $650.00Low
10/6/2023Bank of AmericaBoost Target$600.00 ➝ $700.00Low
10/2/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$630.00Low
9/5/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$630.00Low
9/5/2023ArgusBoost TargetBuy ➝ Buy$470.00 ➝ $620.00Low
9/5/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$617.00 ➝ $640.00Low
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$630.00Low
8/9/2023Morgan StanleyBoost TargetOverweight ➝ Overweight$560.00 ➝ $617.00Low
8/9/2023The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$385.00 ➝ $470.00N/A
8/9/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$550.00N/A
8/9/2023BMO Capital MarketsBoost TargetOutperform ➝ Outperform$565.00 ➝ $633.00Low
8/9/2023Truist FinancialBoost TargetBuy ➝ Buy$525.00 ➝ $600.00Low
8/9/2023BarclaysBoost TargetOverweight ➝ Overweight$500.00 ➝ $590.00Low
8/9/2023JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$510.00 ➝ $600.00Low
8/9/2023Credit Suisse GroupBoost TargetOutperform ➝ Outperform$490.00 ➝ $580.00Low
8/9/2023Bank of AmericaBoost Target$500.00 ➝ $600.00Low
8/8/2023Jefferies Financial GroupUpgradeHold ➝ Buy$408.00 ➝ $615.00Low
8/8/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$490.00 ➝ $580.00Low
8/8/2023Cantor FitzgeraldBoost Target$550.00 ➝ $630.00Low
8/8/2023Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$500.00 ➝ $615.00Low
7/28/2023JPMorgan Chase & Co.Boost TargetOverweight$475.00 ➝ $510.00Low
7/26/2023CitigroupBoost TargetBuy$360.00 ➝ $525.00Low
7/21/2023Jefferies Financial GroupBoost TargetHold$408.00 ➝ $430.00Low
7/21/2023Morgan StanleyBoost TargetOverweight$551.00 ➝ $560.00Low
7/20/2023Truist FinancialBoost TargetBuy$430.00 ➝ $525.00Low
7/18/2023BMO Capital MarketsBoost Target$505.00 ➝ $565.00Low
7/14/2023HSBCInitiated CoverageBuy$560.00Low
6/27/202322nd Century GroupReiterated RatingMaintainsLow
6/27/2023Cantor FitzgeraldBoost Target$485.00 ➝ $550.00Low
6/27/2023BarclaysBoost Target$420.00 ➝ $500.00Low
6/20/2023Berenberg BankBoost Target$375.00 ➝ $500.00Low
5/26/2023Wells Fargo & CompanyBoost Target$440.00 ➝ $500.00Low
5/24/2023UBS GroupBoost TargetBuy$447.00 ➝ $498.00Low
5/24/2023Bank of AmericaBoost TargetBuy$450.00 ➝ $500.00Low
5/15/2023Morgan StanleyBoost Target$478.00 ➝ $507.00Low
5/4/2023BMO Capital MarketsBoost Target$430.00 ➝ $505.00Low
5/4/2023JPMorgan Chase & Co.Boost Target$430.00 ➝ $475.00Low
5/4/2023Credit Suisse GroupBoost Target$420.00 ➝ $490.00Low
5/1/2023SVB SecuritiesBoost Target$410.00 ➝ $458.00Low
5/1/2023BarclaysBoost Target$400.00 ➝ $420.00Low
4/28/20233MReiterated RatingMaintainsLow
4/28/2023Truist FinancialBoost Target$421.00 ➝ $430.00Low
4/28/2023Cantor FitzgeraldBoost Target$432.00 ➝ $485.00Low
4/28/2023Credit Suisse GroupBoost Target$400.00 ➝ $420.00Low
4/28/2023JPMorgan Chase & Co.Boost Target$400.00 ➝ $430.00Low
4/28/2023UBS GroupBoost Target$438.00 ➝ $447.00Low
4/28/2023Wells Fargo & CompanyBoost Target$375.00 ➝ $440.00Low
4/11/2023GuggenheimLower TargetBuy$395.00 ➝ $392.00Low
4/10/2023Morgan StanleyBoost TargetOverweight$444.00 ➝ $448.00Low
4/3/2023Jefferies Financial GroupBoost TargetHold$290.00 ➝ $310.00Low
3/13/2023Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$360.00 ➝ $375.00Low
3/6/2023Jefferies Financial GroupInitiated CoverageHold$290.00Low
3/3/2023CitigroupLower TargetBuy$370.00 ➝ $360.00Low
3/1/2023Morgan StanleyLower TargetOverweight$455.00 ➝ $444.00Low
2/15/2023Societe GeneraleDowngradeHold ➝ Sell$278.00Low
2/3/2023Wells Fargo & CompanyLower TargetEqual Weight$375.00 ➝ $360.00Low
2/3/2023Morgan StanleyBoost TargetOverweight$440.00 ➝ $455.00Low
1/3/2023BarclaysBoost TargetOverweight$395.00 ➝ $400.00Low
12/16/2022SVB LeerinkBoost TargetOutperform$384.00 ➝ $410.00Low
12/15/2022UBS GroupLower TargetBuy$428.00 ➝ $420.00Low
12/14/2022Morgan StanleyLower TargetOverweight$446.00 ➝ $440.00Low
12/14/2022JPMorgan Chase & Co.Boost Target$380.00 ➝ $400.00Low
12/9/2022UBS GroupBoost Target$407.00 ➝ $428.00Low
12/8/2022Wells Fargo & CompanyBoost TargetEqual Weight$365.00 ➝ $375.00Low
12/7/2022GuggenheimBoost TargetBuy$399.00 ➝ $401.00Low
12/6/2022Credit Suisse GroupBoost TargetOutperform$395.00 ➝ $400.00Low
12/6/2022Morgan StanleyBoost TargetOverweight$436.00 ➝ $446.00Low
12/5/2022CowenBoost TargetOutperform$390.00 ➝ $430.00Low
12/5/2022CowenBoost Target$390.00 ➝ $430.00Low
11/22/2022Berenberg BankBoost TargetBuy$345.00 ➝ $375.00Low
11/17/2022Credit Suisse GroupInitiated CoverageOutperform$395.00Low
11/17/2022Morgan StanleyLower TargetOverweight$441.00 ➝ $436.00Low
11/15/2022Truist FinancialBoost Target$400.00 ➝ $421.00Low
11/8/2022The Goldman Sachs GroupBoost TargetNeutral$281.00 ➝ $313.00Low
11/2/2022SVB LeerinkBoost TargetOutperform$341.00 ➝ $384.00Low
11/2/2022Morgan StanleyBoost TargetOverweight$408.00 ➝ $441.00Low
11/2/2022Wells Fargo & CompanyBoost TargetEqual Weight$305.00 ➝ $365.00Low
11/2/2022BarclaysBoost TargetOverweight$355.00 ➝ $395.00Low
10/12/2022Morgan StanleyLower TargetOverweight$412.00 ➝ $408.00Low
9/30/2022ArgusBoost Target$315.00 ➝ $360.00Low
9/22/2022UBS GroupUpgradeNeutral ➝ Buy$335.00 ➝ $363.00Low
9/7/2022Morgan StanleyBoost TargetOverweight$395.00 ➝ $412.00Low
9/6/2022BMO Capital MarketsBoost TargetOutperform$369.00 ➝ $396.00Low
8/25/2022CitigroupBoost Target$285.00 ➝ $370.00Low
7/27/2022UBS GroupBoost TargetOutperform$335.00Low
7/8/2022Morgan StanleyBoost TargetOverweight$369.00 ➝ $395.00N/A
7/7/2022BarclaysBoost TargetOverweight$333.00 ➝ $355.00N/A
6/1/2022JPMorgan Chase & Co.Boost Target$340.00 ➝ $355.00Low
5/23/2022SVB LeerinkInitiated CoverageOutperform$341.00Low
5/2/2022MizuhoBoost Target$315.00 ➝ $356.00Low
4/29/2022Morgan StanleyBoost Target$364.00 ➝ $369.00High
4/29/2022Wells Fargo & CompanyBoost Target$280.00 ➝ $305.00Medium
4/12/2022The Goldman Sachs GroupBoost TargetNeutral$234.00 ➝ $264.00Low
4/6/2022Morgan StanleyBoost TargetOverweight$265.00 ➝ $364.00High
3/17/2022Bank of AmericaBoost Target$300.00 ➝ $315.00Medium
3/10/2022Daiwa Capital MarketsInitiated CoverageOutperform$286.00Medium
2/4/2022MizuhoLower TargetBuy$302.00 ➝ $293.00High
2/4/2022Morgan StanleyLower TargetOverweight$272.00 ➝ $265.00Medium
1/24/2022Morgan StanleyLower TargetOverweight$275.00 ➝ $272.00Low
1/21/2022DZ BankUpgradeHold ➝ Buy$291.00Medium
1/5/2022MizuhoBoost Target$272.00 ➝ $302.00High
1/4/2022Wells Fargo & CompanyBoost TargetEqual Weight$270.00 ➝ $280.00Low
1/3/2022Sanford C. BernsteinBoost TargetMarket Perform$250.00 ➝ $300.00High
12/20/2021Berenberg BankBoost TargetBuy$270.00 ➝ $305.00High
12/20/2021BarclaysBoost TargetOverweight$280.00 ➝ $325.00High
12/17/2021The Goldman Sachs GroupInitiated CoverageNeutral$236.00High
12/16/2021MizuhoInitiated CoverageBuy$272.00Low
12/16/2021BMO Capital MarketsBoost TargetOutperform$311.00 ➝ $320.00Low
12/16/2021Bank of AmericaBoost TargetBuy$285.00 ➝ $300.00Low
12/16/2021JPMorgan Chase & Co.Reiterated RatingBuyLow
12/8/2021Wells Fargo & CompanyInitiated CoverageEqual Weight$270.00Low
11/24/2021Truist FinancialBoost TargetBuy$262.00 ➝ $301.00Low
11/18/2021BMO Capital MarketsInitiated CoverageOutperform$311.00Medium
10/27/2021MizuhoLower TargetBuy$279.00 ➝ $272.00Low
10/11/2021Berenberg BankUpgradeHold ➝ Buy$240.00 ➝ $270.00Low
9/29/2021CitigroupUpgradeNeutral ➝ Buy$210.00 ➝ $265.00High
9/24/2021JPMorgan Chase & Co.Reiterated RatingBuy$300.00Low
8/30/2021CowenBoost TargetOutperform$250.00 ➝ $300.00Low
8/9/2021ArgusBoost TargetBuy$225.00 ➝ $300.00Medium
8/5/2021DZ BankUpgradeHold ➝ Buy$288.00Low
8/4/2021JPMorgan Chase & Co.Boost TargetTop Pick ➝ Overweight$270.00 ➝ $300.00Medium
8/4/2021Morgan StanleyBoost TargetOverweight$207.00 ➝ $275.00High
8/4/2021MizuhoBoost TargetBuy$250.00 ➝ $279.00High
7/27/2021Truist FinancialInitiated CoverageBuy$262.00Low
7/7/2021MizuhoReiterated RatingBuy$250.00Low
7/6/2021BarclaysBoost TargetOverweight$227.00 ➝ $250.00Low
7/2/2021Truist FinancialBoost TargetBuy ➝ Buy$225.00 ➝ $262.00Low
6/24/2021Cantor FitzgeraldBoost TargetPositive ➝ Overweight$245.00 ➝ $300.00High
6/24/2021CowenBoost TargetPositive ➝ Outperform$235.00 ➝ $250.00High
6/15/2021JPMorgan Chase & Co.Boost TargetOverweight$240.00 ➝ $260.00Low
6/14/2021The Goldman Sachs GroupBoost TargetPositive ➝ Conviction-Buy$252.00 ➝ $270.00Low
6/8/2021Truist FinancialReiterated RatingBuy$225.00Medium
4/28/2021Morgan StanleyLower TargetOverweight$217.00 ➝ $207.00Medium
4/28/2021MizuhoLower TargetBuy$228.00 ➝ $216.00Medium
4/28/2021BarclaysLower TargetOverweight$232.00 ➝ $227.00Medium
3/15/2021Truist FinancialBoost TargetBuy$215.00 ➝ $225.00High
2/12/2021CowenBoost TargetOutperform$195.00 ➝ $235.00Low
2/4/2021Morgan StanleyBoost TargetOverweight$190.00 ➝ $217.00Medium
2/1/2021Truist FinancialBoost Target$200.00 ➝ $215.00Low
2/1/2021MizuhoBoost TargetBuy$222.00 ➝ $228.00Low
2/1/2021BarclaysBoost TargetOverweight$190.00 ➝ $232.00Low
1/22/2021Bank of AmericaBoost TargetBuy$195.00 ➝ $225.00Medium
1/19/2021MizuhoUpgradeNeutral ➝ Buy$164.00 ➝ $222.00N/A
1/12/2021Truist FinancialBoost Target$182.00 ➝ $200.00Medium
12/16/2020MizuhoBoost TargetNeutral$156.00 ➝ $164.00High
12/10/2020Wolfe ResearchUpgradePeer Perform ➝ Outperform$147.00 ➝ $183.00Medium
11/17/2020MizuhoLower TargetNeutral$164.00 ➝ $156.00Low
11/10/2020Sanford C. BernsteinInitiated CoverageMarket Perform$150.00Low
10/28/2020Morgan StanleyLower TargetOverweight$176.00 ➝ $170.00Low
10/23/2020Truist FinancialInitiated CoverageBuy$180.00Medium
10/16/2020JPMorgan Chase & Co.Boost TargetOverweight$190.00 ➝ $200.00Low
9/29/2020Berenberg BankInitiated CoverageHold$144.00Medium
9/3/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$149.55 ➝ $176.00High
8/14/2020Morgan StanleyBoost TargetEqual Weight$148.00 ➝ $157.00Low
6/29/2020MizuhoBoost TargetNeutral$155.00 ➝ $164.00Low
6/19/2020Bank of AmericaReiterated RatingBuy$180.00Low
6/17/2020JPMorgan Chase & Co.Boost TargetOverweight$175.00 ➝ $190.00Low
6/16/2020GuggenheimUpgradeNeutral ➝ Buy$182.00High
4/24/2020MizuhoBoost TargetBuy$148.00 ➝ $155.00Low
4/24/2020CfraBoost TargetHold$146.00 ➝ $167.00Low
4/24/2020Cantor FitzgeraldBoost TargetOverweight$156.00 ➝ $185.00Low
4/20/2020UBS GroupDowngradeBuy ➝ Neutral$157.00 ➝ $158.00High
4/19/2020Morgan StanleyDowngradeOverweight ➝ Equal WeightLow
4/15/2020CowenBoost TargetOutperform$145.00 ➝ $160.00Medium
4/9/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$148.00Low
4/2/2020MizuhoReiterated RatingHold$148.00Medium
4/2/2020Morgan StanleyLower TargetOverweight ➝ Equal Weight$150.00 ➝ $148.00High
3/11/2020The Goldman Sachs GroupUpgradeBuy ➝ Conviction-Buy$168.00Medium
2/27/2020BarclaysInitiated CoverageOverweightHigh
2/18/2020Cantor FitzgeraldReiterated RatingBuy$156.00Low
2/5/2020MizuhoInitiated CoverageNeutral$148.00Low
2/3/2020Cantor FitzgeraldReiterated RatingBuy$156.00Medium
12/30/2019ArgusBoost TargetBuy$145.00 ➝ $165.00Low
12/18/2019JPMorgan Chase & Co.Boost TargetOverweight$140.00 ➝ $150.00High
12/18/2019Morgan StanleyUpgradeEqual Weight ➝ Overweight$116.00 ➝ $150.00High
12/2/2019Cantor FitzgeraldReiterated RatingBuy$143.00Low
10/17/2019UBS GroupLower TargetBuy$134.00 ➝ $133.00Low
10/16/2019Bank of AmericaInitiated CoverageBuy$133.00Low
9/10/2019Bank of AmericaSet TargetNeutral$118.00 ➝ $120.00High
5/28/2019The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$135.00Low
5/1/2019BMO Capital MarketsBoost TargetOutperform ➝ Outperform$130.00 ➝ $133.00Low
4/30/2019Cantor FitzgeraldReiterated RatingBuy$143.00Medium
4/23/2019Edward JonesUpgradeHold ➝ Buy$117.49Low
4/22/2019BMO Capital MarketsLower TargetOutperform$130.00Medium
4/14/2019BarclaysReiterated RatingBuy$140.00Low
4/11/2019GuggenheimDowngradeBuy ➝ Neutral$125.84Low
3/22/2019Credit Suisse GroupSet TargetHold$121.00Low
3/21/2019Bank of AmericaSet TargetHold$129.00Low
3/20/2019UBS GroupInitiated CoverageBuy$140.00 ➝ $74.51Low
3/12/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$140.00Low
2/26/2019CitigroupSet TargetHold$124.00Medium
2/8/2019UBS GroupLower TargetAverage$107.53 ➝ $100.00Low
2/4/2019Cantor FitzgeraldReiterated RatingBuyLow
1/23/2019UBS GroupInitiated CoverageBuy ➝ Buy$131.00Low
1/20/2019BarclaysReiterated RatingBuy$130.00Low
12/27/2018ArgusReiterated RatingBuyMedium
12/24/2018BMO Capital MarketsBoost TargetOutperform$124.00 ➝ $132.00Low
12/20/2018Morgan StanleySet TargetHold$116.00High
12/19/2018BMO Capital MarketsReiterated RatingBuyLow
12/2/2018CitigroupDowngradeBuy ➝ Neutral$113.00Low
(Data available from 11/30/2018 forward)

News Sentiment Rating

0.57 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 43 very positive mentions
  • 86 positive mentions
  • 21 negative mentions
  • 6 very negative mentions
  • 31 very positive mentions
  • 48 positive mentions
  • 1 negative mentions
  • 7 very negative mentions
  • 41 very positive mentions
  • 48 positive mentions
  • 16 negative mentions
  • 5 very negative mentions
  • 39 very positive mentions
  • 56 positive mentions
  • 7 negative mentions
  • 2 very negative mentions
  • 40 very positive mentions
  • 56 positive mentions
  • 12 negative mentions
  • 6 very negative mentions
  • 47 very positive mentions
  • 36 positive mentions
  • 8 negative mentions
  • 6 very negative mentions
  • 55 very positive mentions
  • 66 positive mentions
  • 8 negative mentions
  • 21 very negative mentions
  • 48 very positive mentions
  • 72 positive mentions
  • 17 negative mentions
  • 8 very negative mentions

Current Sentiment

  • 48 very positive mentions
  • 72 positive mentions
  • 17 negative mentions
  • 8 very negative mentions

Recent Stories by Sentiment

Eli Lilly and Company logo
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Read More

Today's Range

Now: $591.04
Low: $586.21
High: $596.23

50 Day Range

MA: $579.57
Low: $525.10
High: $619.50

52 Week Range

Now: $591.04
Low: $309.20
High: $629.97


5,388,421 shs

Average Volume

3,084,120 shs

Market Capitalization

$561.08 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Eli Lilly and Company?

The following sell-side analysts have issued reports on Eli Lilly and Company in the last twelve months: 22nd Century Group, Inc., 3M, Argus, Bank of America Co., Barclays PLC, Berenberg Bank, BMO Capital Markets, Cantor Fitzgerald, Citigroup Inc., Cowen Inc, Cowen Inc., Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Guggenheim, HSBC Holdings plc, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Royal Bank of Canada, Societe Generale, StockNews.com, SVB Leerink LLC, SVB Securities, The Goldman Sachs Group, Inc., Truist Financial Co., UBS Group AG, and Wells Fargo & Company.
View the latest analyst ratings for LLY.

What is the current price target for Eli Lilly and Company?

24 Wall Street analysts have set twelve-month price targets for Eli Lilly and Company in the last year. Their average twelve-month price target is $559.08, suggesting a possible downside of 5.1%. Morgan Stanley has the highest price target set, predicting LLY will reach $722.00 in the next twelve months. Societe Generale has the lowest price target set, forecasting a price of $278.00 for Eli Lilly and Company in the next year.
View the latest price targets for LLY.

What is the current consensus analyst rating for Eli Lilly and Company?

Eli Lilly and Company currently has 1 sell rating, 2 hold ratings and 18 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for LLY.

What other companies compete with Eli Lilly and Company?

How do I contact Eli Lilly and Company's investor relations team?

Eli Lilly and Company's physical mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The company's listed phone number is (317) 276-2000 and its investor relations email address is johnson_philip[email protected]. The official website for Eli Lilly and Company is www.lilly.com. Learn More about contacing Eli Lilly and Company investor relations.